Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines.
Fas ligand (FasL) is involved in tumor evasion from the immune system. We analyzed 22 human gliomas for expression of FasL and its receptor, Fas. Positive FasL and Fas immunoreactivity was detected in 13 out of 22 tumors by Western blotting and in 15 out of 22 tumors by immunohistochemistry. Immunohistochemistry also showed that Fas and FasL expression was confined to tumor cells. Co-expression of these molecules was confirmed by Western blotting and immunohistochemistry in 4 of 7 glioma cell lines. Co-expression of FasL and Fas within tumor cells suggests that their contribution in vivo to the process of immune system evasion and tumor cell apoptosis is complex and probably involves additional factors.
Husain
N
N
Molecular Neuro-oncology Laboratories, Massachusetts General Hospital, Charlestown 02129, USA.
Chiocca
E A
EA
Rainov
N
N
Louis
D N
DN
Zervas
N T
NT
D001254:Astrocytoma / Q000737:chemistry* / Q000473:pathology; D015153:Blotting, Western; D053222:Fas Ligand Protein; D005909:Glioblastoma / Q000737:chemistry* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008024:Ligands; D008562:Membrane Glycoproteins / Q000032:analysis*; D014407:Tumor Cells, Cultured / Q000737:chemistry; D019014:fas Receptor / Q000032:analysis*
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008024:Ligands; D008562:Membrane Glycoproteins; D019014:fas Receptor